Market cap
$5,588 Mln
Revenue (TTM)
$1,382 Mln
P/E Ratio
54.3
P/B Ratio
6.1
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 5.42 | 9.30 | 4.11 | 3.71 | 8.16 |
| EBIT | 57.90 | 28.42 | -35.54 | -3.35 | 12.67 |
| Net Profit | 40.28 | 19.70 | -38.22 | -6.78 | 27.17 |
| EPS | 37.98 | 22.79 | -34.79 | -3.68 | 29.88 |
| Book Value | -- | -- | 3.84 | 2.56 | 3.67 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-26 | Mar-25 |
| EBIT-Margin
| 15.24 | 14.12 | 12.14 | 11.75 | 18.16 |
| Net Margin
| -- | 7.22 | 7.52 | -- | -- |
| Return on equity
| 14.70 | 12.93 | 12.26 | 12.03 | 18.83 |
| Return on Capital
| 6.87 | 6.17 | -- | 4.79 | 8.79 |
| Return on Assets
| 5.64 | 5.07 | 3.64 | 4.02 | 7.22 |
| Debt to Equity (x)
| -- | -- | 1.24 | 1.54 | 1.49 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Haemonetics (HAE)
|
--
|
4.79
|
8.79
|
7.01
|
7.41
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
12.26
Higher than Peers by 5.75
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Haemonetics (HAE)
|
12.26
|
12.03
|
18.83
|
13.22
|
14.72
|
|
Peer Median
|
6.51
|
--
|
--
|
--
|
--
|
ROA
3.64
Higher than Peers by 0.68
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Haemonetics (HAE)
|
3.64
|
4.02
|
7.22
|
5.69
|
6.08
|
|
Peer Median
|
2.96
|
--
|
--
|
--
|
--
|
EBIT Margin
12.14
Higher than Peers by 1.45
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Haemonetics (HAE)
|
12.14
|
11.75
|
18.16
|
15.80
|
14.31
|
|
Peer Median
|
10.69
|
--
|
--
|
--
|
--
|
Net Margin
7.52
Higher than Peers by 0.53
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Haemonetics (HAE)
|
7.52
|
7.29
|
12.32
|
8.98
|
10.00
|
|
Peer Median
|
6.99
|
--
|
--
|
--
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Haemonetics (HAE)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
4.11
Lower than Peers by 5.15
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Haemonetics (HAE)
|
4.11
|
-0.02
|
0.04
|
0.12
|
0.18
|
|
Peer Median
|
9.26
|
--
|
--
|
--
|
--
|
EBIT Growth
-35.54
Lower than Peers by 48.31
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Haemonetics (HAE)
|
-35.54
|
-36.57
|
19.47
|
23.71
|
58.98
|
|
Peer Median
|
12.76
|
--
|
--
|
--
|
--
|
Net Profit Growth
-38.22
Lower than Peers by 52.05
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Haemonetics (HAE)
|
-38.22
|
-41.97
|
42.64
|
1.87
|
166.05
|
|
Peer Median
|
13.83
|
--
|
--
|
--
|
--
|
EPS Growth
-34.79
Lower than Peers by 55.30
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Haemonetics (HAE)
|
-34.79
|
-0.38
|
0.48
|
0.01
|
1.67
|
|
Peer Median
|
20.51
|
--
|
--
|
--
|
--
|
Book Value Growth
8.54
Higher than Peers by 0.46
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Haemonetics (HAE)
|
8.54
|
--
|
--
|
--
|
--
|
|
Peer Median
|
8.09
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
1.24
Higher than Peers by 0.87
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Haemonetics (HAE)
|
1.24
|
1.54
|
1.49
|
0.84
|
0.94
|
|
Peer Median
|
0.37
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.01
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Haemonetics (HAE)
|
0.01
|
0.01
|
0.37
|
0.01
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
2.84
Higher than Peers by 0.02
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Haemonetics (HAE)
|
2.84
|
2.95
|
1.62
|
2.56
|
3.06
|
|
Peer Median
|
2.82
|
--
|
--
|
--
|
--
|
Quick Ratio
1.83
Lower than Peers by 0.26
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Haemonetics (HAE)
|
1.83
|
1.87
|
0.99
|
1.50
|
2.03
|
|
Peer Median
|
2.09
|
--
|
--
|
--
|
--
|
Interest Coverage
4.98
Lower than Peers by 1.13
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Haemonetics (HAE)
|
4.98
|
5.46
|
25.35
|
15.89
|
11.43
|
|
Peer Median
|
6.12
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
16.27
Lower than Peers by 0.15
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Haemonetics (HAE)
|
16.27
|
16.26
|
14.89
|
15.78
|
15.33
|
|
Peer Median
|
16.42
|
--
|
--
|
--
|
--
|
Asset Turnover
0.48
Lower than Peers by 0.02
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Haemonetics (HAE)
|
0.48
|
0.55
|
0.59
|
0.63
|
0.62
|
|
Peer Median
|
0.50
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Haemonetics (HAE)
|
--
|
57.43
|
54.92
|
53.81
|
52.90
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Haemonetics (HAE)
|
--
|
207.70
|
214.01
|
176.34
|
184.84
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Haemonetics (HAE)
|
--
|
36.51
|
44.02
|
41.99
|
40.92
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Haemonetics (HAE)
|
--
|
228.62
|
224.91
|
188.16
|
196.82
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
54.30
Higher than Peers by 8.13
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Haemonetics (HAE)
|
54.30
|
26.77
|
18.75
|
37.32
|
36.73
|
|
Peer Median
|
46.16
|
--
|
--
|
--
|
--
|
Price / Book Value
6.11
Higher than Peers by 1.23
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Haemonetics (HAE)
|
6.11
|
3.27
|
3.83
|
4.57
|
5.18
|
|
Peer Median
|
4.88
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Haemonetics (HAE)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
22.17
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Haemonetics (HAE)
|
22.17
|
13.35
|
11.20
|
16.49
|
18.11
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
5,588
Higher than Peers by 4,923
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Haemonetics (HAE)
|
5,588
|
--
|
--
|
--
|
--
|
|
Peer Median
|
664
|
--
|
--
|
--
|
--
|